文献速递妇科

网片植入、网片套件或自体组织修补用于女性复发性前/后壁脱垂手术:随机对照试验(PROSPECT)

Mesh inlay, mesh kit or native tissue repair for women having repeat anterior or posterior prolapse surgery: randomised controlled trial (PROSPECT).
PubMed 文献 · BJOG · 2020-04-06

1年时盆腔器官脱垂症状评分各组相似,但置信区间未排除最小临床重要差异;2年网片暴露率网片植入组13%、网片套件组9%。结论:未发现网片植入或套件在改善脱垂症状方面优于标准修补的证据。

要点

  • 复发性脱垂手术中,网片植入或网片套件与标准自体组织修补相比,1年症状评分无显著差异。
  • 2年累积网片暴露率:网片植入组13%(7/52),网片套件组9%(4/46)。
  • 样本量不足以得出确定性结论,结果可贡献于未来meta分析。

核心结论

  • 在复发性脱垂手术女性中,未发现使用网片植入或网片套件与标准自体组织修补在脱垂症状方面存在差异的证据。

主要发现

  • 1年平均盆腔器官脱垂症状评分:标准修补6.6 vs 网片植入6.1,平均差-0.41(95%CI -2.92至2.11)。
  • 1年平均盆腔器官脱垂症状评分:标准修补6.6 vs 网片套件5.9,平均差-1.21(95%CI -4.13至1.72)。
  • 1年严重不良事件(除外网片暴露):标准修补7/55(13%)vs 网片植入5/52(10%),风险比1.05(95%CI 0.66-1.68)。
  • 1年严重不良事件:标准修补3/25(12%)vs 网片套件3/46(7%),风险比0.49(95%CI 0.11-2.16)。
  • 2年累积网片暴露率:网片植入组7/52(13%),其中4例需手术修正;网片套件组4/46(9%),其中2例需手术修正。

临床怎么用

  • 对于复发性前/后壁脱垂手术,现有证据不支持常规使用合成网片植入或网片套件替代标准自体组织修补。

局限性

  • 样本量太小,无法得出确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare standard (native tissue) repair with synthetic mesh inlays or mesh kits. DESIGN: Randomised controlled trial. SETTING: Thirty-three UK hospitals. POPULATION: Women having surgery for recurrent prolapse. METHODS: Women recruited using remote randomisation. MAIN OUTCOME MEASURES: Prolapse symptoms, condition-specific quality-of-life and serious adverse effects. RESULTS: A Mean Pelvic Organ Prolapse Symptom Score at 1 year was similar for each comparison (standard 6.6 versus mesh inlay 6.1, mean difference [MD] -0.41, 95% CI -2.92 to 2.11: standard 6.6 versus mesh kit 5.9, MD -1.21 , 95% CI -4.13 to 1.72) but the confidence intervals did not exclude a minimally important clinical difference. There was no evidence of difference in any other outcome measure at 1 or 2 years. Serious adverse events, excluding mesh exposure, were similar at 1 year (standard 7/55 [13%] versus mesh inlay 5/52 [10%], risk ratio [RR] 1.05 [0.66-1.68]: standard 3/25 [12%] versus mesh kit 3/46 [7%], RR 0.49 [0.11-2.16]). Cumulative mesh exposure rates over 2 years were 7/52 (13%) in the mesh inlay arm, of whom four women required surgical revision; and 4/46 in the mesh kit arm (9%), of whom two required surgical revision. CONCLUSIONS: We did not find evidence of a difference in terms of prolapse symptoms from the use of mesh inlays or mesh kits in women undergoing repeat prolapse surgery. Although the sample size was too small to be conclusive, the results provide a substantive contribution to future meta-analysis. TWEETABLE ABSTRACT: There is not enough evidence to support use of synthetic mesh inlay or mesh kits for repeat prolapse surgery.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Glazener C, Breeman S, Elders A, et al. Mesh inlay, mesh kit or native tissue repair for women having repeat anterior or posterior prolapse surgery: randomised controlled trial (PROSPECT). BJOG. 2020. PMID: 32141709. doi:10.1111/1471-0528.16197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。